Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Susie Jun, Philippe Beuzeboc et al.|European Journal of Cancer|2012Cited by 588
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison Stopeck, Ada Braun, Karim Fizazi et al.|Supportive Care in Cancer|2015Cited by 190
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsAllan Lipton, Ada Braun, Karim Fizazi et al.|European Journal of Cancer|2015Cited by 114
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acidRoger von Moos, Karen Chung, Jean-Jacques Body et al.|Supportive Care in Cancer|2013Cited by 94
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastasesRoger von Moos, Yi Qian, Jean-Jacques Body et al.|Supportive Care in Cancer|2015Cited by 79